TELA BIO, INC. (TELA): Price and Financial Metrics


TELA BIO, INC. (TELA): $12.73

0.24 (+1.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TELA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

TELA POWR Grades


  • Sentiment is the dimension where TELA ranks best; there it ranks ahead of 86.38% of US stocks.
  • The strongest trend for TELA is in Value, which has been heading up over the past 47 weeks.
  • TELA's current lowest rank is in the Quality metric (where it is better than 27.54% of US stocks).

TELA Stock Summary

  • TELA has a market capitalization of $184,229,769 -- more than approximately only 19.38% of US stocks.
  • TELA Bio Inc's stock had its IPO on November 8, 2019, making it an older stock than just 3% of US equities in our set.
  • As for revenue growth, note that TELA's revenue has grown 51.93% over the past 12 months; that beats the revenue growth of 87.28% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to TELA Bio Inc are LNN, XGN, SPNE, PWFL, and HAE.
  • Visit TELA's SEC page to see the company's official filings. To visit the company's web site, go to www.telabio.com.

TELA Valuation Summary

  • TELA's price/earnings ratio is -5.9; this is 116.16% lower than that of the median Healthcare stock.
  • Over the past 22 months, TELA's EV/EBIT ratio has gone up 2.3.
  • Over the past 22 months, TELA's price/sales ratio has gone down 9.4.

Below are key valuation metrics over time for TELA.

Stock Date P/S P/B P/E EV/EBIT
TELA 2021-08-31 7.8 5.4 -5.9 -5.7
TELA 2021-08-30 8.0 5.6 -6.1 -5.8
TELA 2021-08-27 7.9 5.5 -6.1 -5.8
TELA 2021-08-26 8.2 5.7 -6.2 -6.0
TELA 2021-08-25 8.2 5.7 -6.2 -6.0
TELA 2021-08-24 8.2 5.7 -6.3 -6.0

TELA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TELA has a Quality Grade of C, ranking ahead of 27.61% of graded US stocks.
  • TELA's asset turnover comes in at 0.295 -- ranking 132nd of 182 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows TELA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.295 0.635 -0.825
2021-03-31 0.230 0.614 -0.754
2020-12-31 0.217 0.617 -0.700
2020-09-30 0.220 0.605 -0.624
2020-06-30 0.260 0.613 -0.546
2019-12-31 0.325 0.600 -0.536

TELA Price Target

For more insight on analysts targets of TELA, see our TELA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.25 (Strong Buy)

TELA Stock Price Chart Interactive Chart >

Price chart for TELA

TELA Price/Volume Stats

Current price $12.73 52-week high $18.00
Prev. close $12.49 52-week low $11.03
Day low $12.51 Volume 4,500
Day high $12.75 Avg. volume 37,217
50-day MA $14.00 Dividend yield N/A
200-day MA $14.49 Market Cap 184.23M

TELA BIO, INC. (TELA) Company Bio


TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.


TELA Latest News Stream


Event/Time News Detail
Loading, please wait...

TELA Latest Social Stream


Loading social stream, please wait...

View Full TELA Social Stream

Latest TELA News From Around the Web

Below are the latest news stories about TELA Bio Inc that investors may wish to consider to help them evaluate TELA as an investment opportunity.

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

Positive results presented at the 2021 Society of American Gastrointestinal and Endoscopic Surgeons Meeting show advancement in hernia repair options Positive results presented at the 2021 Society of American Gastrointestinal and Endoscopic Surgeons Meeting show advancement in hernia repair options

Intrado Digital Media | September 13, 2021

Is TELA Bio (NASDAQ:TELA) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | September 9, 2021

TELA Bio''s OviTex® Reinforced Tissue Matrix to be Featured in Three Presentations at SAGES 2021

Innovative medtech company celebrates upcoming poster presentations for its advanced hernia reinforcement material at industry-leading conference Innovative medtech company celebrates upcoming poster presentations for its advanced hernia reinforcement material at industry-leading conference

Intrado Digital Media | August 16, 2021

TELA Bio's OviTex® Reinforced Tissue Matrix to be Featured in Three Presentations at SAGES 2021

Innovative medtech company celebrates upcoming poster presentations for its advanced hernia reinforcement material at industry-leading conferenceMALVERN, Pa., Aug. 16, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced three upcoming poster presentations on its OviTex Reinforced Tissue Ma

Yahoo | August 16, 2021

TELA Bio, Inc. (TELA) Q2 2021 Earnings Call Transcript

Joining me on today's call is Tony Koblish, president and CEO; and Megan Smeykal, vice president and corporate controller. As with the original BRAVO study, we expect to enroll up to 100 subjects with patient follow-ups at 90 days, 12 months, and 24 months.

Yahoo | August 12, 2021

Read More 'TELA' Stories Here

TELA Price Returns

1-mo -10.10%
3-mo -15.13%
6-mo -19.12%
1-year -18.45%
3-year N/A
5-year N/A
YTD -15.36%
2020 16.14%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7817 seconds.